Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30148832 | 1.00 | EGFR (0.37) | EGFR | |
| Pyrrole SCHEMBL81014 | 0.87 | EGFR (0.33) | EGFR | |
| SCHEMBL127479 | 0.79 | EGFR (0.50) | EGFR | |
| SCHEMBL28003243 | 0.76 | EGFR (0.48) | EGFR | |
| SCHEMBL29464263 | 0.74 | PIK3CG (0.38) | EGFR | |
| SCHEMBL29946334 | 0.67 | — | — | |
| SCHEMBL11882020 | 0.66 | EGFR (0.37) | EGFR | |
| SCHEMBL29389802 | 0.65 | ALDH1A1 (0.44) | — | |
| SCHEMBL162279 | 0.65 | ALDH1A1 (0.44) | — | |
| SCHEMBL30826363 | 0.65 | EGFR (0.35) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-07-25 | — | — | US | claimed |
| EP-4242202-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-09-13 | — | — | EP | claimed |
| CN-116217558-A | GLP-1 receptor agonist, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-115703792-A | Tricyclic derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-02-17 | — | — | CN | claimed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-114763352-A | GLP-1 receptor agonist and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-07-19 | — | — | CN | claimed |
| WO-2022111624-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-06-02 | — | — | WO | claimed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | claimed |
| EP-2336315-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | claimed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | claimed |
| EP-4219463-B1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-115594669-B | Parallel ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-115703792-B | Tricycle derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-116178345-B | Substituted pyrimidinyl-pyridinyl-pyridone compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| WO-2006131835-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006120573-A2 | HETEROCYCLIC N-OXIDES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
| US-20050096333-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-05-05 | — | — | US | disclosed |
| CN-1610683-A | Pyrimido triazines as phosphatase inhibitors | HOFFMANN LA ROCHE (CH) | 2005-04-27 | — | — | CN | disclosed |
| WO-2005032481-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GLP1R, GIPR, GCGR | EGFR 1993/4885 |
| US-20050096333-A1 | Quinazoline derivatives as medicaments | HRH4, HRH2, HRH3 | EGFR 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.